Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 7/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22816877 | 0.89 | CYP19A1 (0.47) | AKR1C3CYP19A1MAPTSMN1; SMN2ERCC5 | |
| SCHEMBL22816823 | 0.87 | CYP19A1 (0.48) | AKR1C3CYP19A1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL22816319 | 0.87 | AKR1C3 (0.49) | AKR1C3CYP19A1MAPT | |
| SCHEMBL22815728 | 0.87 | CYP19A1 (0.59) | CYP19A1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL28047047 | 0.86 | CYP19A1 (0.50) | AKR1C3CYP19A1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL22816876 | 0.86 | CYP19A1 (0.46) | AKR1C3CYP19A1MAPT | |
| SCHEMBL22816326 | 0.86 | CYP19A1 (0.44) | AKR1C3CYP19A1MAPTSMN1; SMN2 | |
| SCHEMBL22795533 | 0.85 | CYP19A1 (0.57) | AKR1C3CYP19A1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL22816187 | 0.85 | CYP19A1 (0.44) | AKR1C3CYP19A1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL23319975 | 0.84 | CYP19A1 (0.47) | AKR1C3CYP19A1MAPTSMN1; SMN2ERCC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | AKR1C3 345/4885CYP19A1 1433/4885MAPT 1215/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | AKR1C3 345/4885CYP19A1 1433/4885MAPT 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.